NALCN is a potential biomarker and therapeutic target in human cancers

por He, Jian, Xu, Jie, Chang, Zhiwei, Yan, Jiaqin, Zhang, Limin, Qin, Yanru
Publicado 2023

Folate receptor-positive circulating tumor cell count, lymphocyte count and derived neutrophil-to- lymphocyte ratio for diagnosing lung cancer relapse

por Wang, Huanrong, Liu, Lei, Yan, Jiaqin, Ma, Wang, Du, Yabing, Zhang, Tengfei
Publicado 2023

Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma

por Yan, Jiaqin, Yuan, Wei, Zhang, Junhui, Li, Ling, Zhang, Lei, Zhang, Xudong, Zhang, Mingzhi
Publicado 2022

Identification of Prognostic Related Genes of Tumor Microenvironment Derived From Esophageal Cancer Patients

por Yuan, Wei, Yan, Jiaqin, Liu, Hongtao, Li, Ling, Wu, BoWen, Guo, Can, Zhang, Mingzhi
Publicado 2021

Strategies to overcome CAR-T cell resistance in clinical work: A single-institute experience

por Nan, Feifei, Fu, Xiaorui, Chen, Xinfeng, Li, Ling, Li, Xin, Wu, Jingjing, Feng, Xiaoyan, Wu, Xiaolong, Yan, Jiaqin, Zhang, Mingzhi
Publicado 2022

Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study

por Ren, Liangliang, Li, Ling, Zhang, Lei, Li, Xin, Fu, Xiaorui, Wang, Xinhua, Wu, Jingjing, Sun, Zhenchang, Feng, Xiaoyan, Chang, Yu, Zhou, Zhiyuan, Nan, Feifei, Yan, Jiaqin, Kong, Fei, Zhang, Mingzhi
Publicado 2021

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma

por Kong, Xiaoshuang, Zhang, Xudong, Ding, Mengjie, Feng, Xiaoyan, Dong, Meng, Zhang, Lei, Fu, Xiaorui, Li, Ling, Li, Xin, Sun, Zhenchang, Yan, Jiaqin, Wang, Xinhua, Wu, Xiaolong, Chen, Qingjiang, Zhang, Mingzhi, Zhu, Linan
Publicado 2023

Follicular dendritic cell sarcoma of the pharyngeal region

por HU, TENGPENG, WANG, XINHUA, YU, CHANG, YAN, JIAQIN, ZHANG, XUNDONG, LI, LING, LI, XIN, ZHANG, LEI, WU, JINGJING, MA, WANG, LI, WENCAI, WANG, GUANNAN, ZHAO, WUGAN, GAO, XIANZHENG, ZHANG, DANDAN, ZHANG, MINGZHI
Publicado 2013

An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma

por Li, Ling, Xiao, Sa, Zhang, Lei, Li, Xin, Fu, Xiaorui, Wang, Xinhua, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Chang, Yu, Nan, Feifei, Yan, Jiaqin, Li, Zhaoming, Shi, Mengyuan, Young, Ken H., Zhang, Mingzhi
Publicado 2018

Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?

por Zhang, Xudong, Fu, Xiaorui, Dong, Meng, Yang, Zhenzhen, Wu, Shaoxuan, Ma, Mijing, Li, Zhaoming, Wang, Xinhua, Li, Ling, Li, Xin, Sun, Zhenchang, Chang, Yu, Nan, Feifei, Yan, Jiaqin, Mao, Yun, Zhang, Mingzhi, Chen, Qingjiang
Publicado 2018

Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial

por Wu, Jingjing, Duan, Lingling, Zhang, Lei, Sun, Zhenchang, Fu, Xiaorui, Li, Xin, Li, Ling, Wang, Xinhua, Zhang, Xudong, Li, Zhaoming, Yu, Hui, Chang, Yu, Nan, Feifei, Yan, Jiaqin, Tian, Li, Wang, Xiaoli, Zhang, Mingzhi
Publicado 2018

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients

por Sun, Yuanyuan, Li, Ling, Li, Xin, Zhang, Lei, Wang, Xinhua, Fu, Xiaorui, Sun, Zhenchang, Zhang, Xudong, Li, Zhaoming, Wu, Jingjing, Yu, Hui, Chang, Yu, Yan, Jiaqin, Wu, Xiaolong, Zhou, Zhiyuan, Nan, Feifei, Tian, Li, Zhang, Mingzhi
Publicado 2020

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

por Du, Lijun, Zhang, Lei, Li, Ling, Li, Xin, Yan, Jiaqin, Wang, Xinhua, Fu, Xiaorui, Sun, Zhenchang, Zhang, Xudong, Li, Zhaoming, Wu, Jingjing, Yu, Hui, Chang, Yu, Zhou, Zhiyuan, Nan, Feifei, Wu, Xiaolong, Tian, Li, Zhang, Mingzhi
Publicado 2020

Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma

por Li, Xin, Cheng, Yasong, Zhang, Mingzhi, Yan, Jiaqin, Li, Ling, Fu, Xiaorui, Zhang, Xudong, Chang, Yu, Sun, Zhenchang, Yu, Hui, Zhang, Lei, Wang, Xinhua, Wu, Jingjing, Li, Zhaoming, Nan, Feifei, Tian, Li, Li, Wencai, Young, Ken H.
Publicado 2018

AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma

por Yan, Jiaqin, Zhang, Junhui, Zhang, Xudong, Li, Xin, Li, Ling, Li, Zhaoming, Chen, Renyin, Zhang, Lei, Wu, Jingjing, Wang, Xinhua, Sun, Zhenchang, Fu, Xiaorui, Chang, Yu, Nan, Feifei, Yu, Hui, Wu, Xiaolong, Feng, Xiaoyan, Li, Wencai, Zhang, Mingzhi
Publicado 2018

Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim a...

por Zhang, Lei, Jia, Sisi, Ma, Yangyang, Li, Ling, Li, Xin, Wang, Xinhua, Fu, Xiaorui, Ma, Wang, Qin, Yanru, Li, Wencai, Wu, Jingjing, Sun, Zhenchang, Zhang, Xudong, Nan, Feifei, Chang, Yu, Li, Zhaoming, Zhang, Dandan, Wang, Guannan, Yan, Jiaqin, Su, Liping, Wang, Jinghua, Xue, Hongwei, Young, Ken H., Zhang, Mingzhi
Publicado 2016

Recurrent PDGFRB mutations in unicentric Castleman disease

por Li, Zhaoming, Lan, Xuan, Li, Chaoping, Zhang, Yanjie, Wang, Yingjun, Xue, Weili, Lu, Lisha, Jin, Mengyuan, Zhou, Zhiyuan, Wang, Xinhua, Li, Ling, Zhang, Lei, Li, Xin, Fu, Xiaorui, Sun, Zhenchang, Wu, Jingjing, Zhang, Xudong, Yu, Hui, Nan, Feifei, Chang, Yu, Yan, Jiaqin, Wu, Xiaolong, Wang, Guannan, Zhang, Dandan, Zhang, Yuan, Young, Ken H., Zhang, Mingzhi
Publicado 2019

Recurrent GNAQ mutation encoding T96S in natural killer/T cell lymphoma

por Li, Zhaoming, Zhang, Xudong, Xue, Weili, Zhang, Yanjie, Li, Chaoping, Song, Yue, Mei, Mei, Lu, Lisha, Wang, Yingjun, Zhou, Zhiyuan, Jin, Mengyuan, Bian, Yangyang, Zhang, Lei, Wang, Xinhua, Li, Ling, Li, Xin, Fu, Xiaorui, Sun, Zhenchang, Wu, Jingjing, Nan, Feifei, Chang, Yu, Yan, Jiaqin, Yu, Hui, Feng, Xiaoyan, Wang, Guannan, Zhang, Dandan, Fu, Xuefei, Zhang, Yuan, Young, Ken H., Li, Wencai, Zhang, Mingzhi
Publicado 2019